Rossari Biotech 将来の成長
Future 基準チェック /16
Rossari Biotechは、12.9%と9%でそれぞれ年率12.9%で利益と収益が成長すると予測される一方、EPSはgrowで12.9%年率。
主要情報
12.9%
収益成長率
12.88%
EPS成長率
| Chemicals 収益成長 | 17.9% |
| 収益成長率 | 9.0% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 21 Jul 2026 |
今後の成長に関する最新情報
分析記事 • Jan 22
Analysts Have Lowered Expectations For Rossari Biotech Limited (NSE:ROSSARI) After Its Latest Results
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...分析記事 • May 03
Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report
Last week, you might have seen that Rossari Biotech Limited ( NSE:ROSSARI ) released its full-year result to the...Recent updates
ナラティブ更新 • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.
ナラティブ更新 • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.ナラティブ更新 • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.ナラティブ更新 • May 14
ROSSARI: New R&D Consolidation And Board Decisions Will Drive Future Upside
Analysts now set a revised price target for Rossari Biotech at ₹601.75, down from ₹635.50, reflecting slightly softer assumptions around revenue growth, profit margins, and future P/E multiples. What's in the News Rossari Biotech has set up a new Research and Development Facility at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai 400 710.分析記事 • May 04
Rossari Biotech's (NSE:ROSSARI) Profits Appear To Have Quality Issues
Rossari Biotech Limited's ( NSE:ROSSARI ) stock didn't jump after it announced some healthy earnings. We did some...ナラティブ更新 • Apr 25
ROSSARI: Upcoming Board Meeting And Dividend Decision Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.5, with only small technical tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, so the headline price target remains unchanged. What's in the News Board meeting scheduled for April 27, 2026, to review and approve audited standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026 (company filing).ナラティブ更新 • Apr 09
ROSSARI: Greenfield Expansion And Subsidiary Restructuring Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.50, citing only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions rather than any major shift in the core outlook. What's in the News A board meeting is scheduled on January 17, 2026 at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).ナラティブ更新 • Mar 26
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have maintained the fair value estimate for Rossari Biotech at ₹635.5, making only minor technical adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E, which result in an essentially unchanged price target view. What's in the News A board meeting is scheduled for January 17, 2026, at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).ナラティブ更新 • Mar 08
ROSSARI: Greenfield Expansion And Subsidiary Buildout Will Support Future Upside
Analysts have maintained Rossari Biotech's fair value estimate at ₹635.50, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E to reflect updated modelling assumptions rather than a change in conviction. What's in the News A board meeting is scheduled on Jan 17, 2026 at 12:30 Indian Standard Time to consider unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).ナラティブ更新 • Feb 22
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹635.5, with the unchanged price target reflecting only marginal tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Board meeting scheduled for January 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider several key corporate actions, including new projects and asset changes (company filing).ナラティブ更新 • Feb 05
ROSSARI: Greenfield Expansion And Subsidiary Reshaping Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for Rossari Biotech slightly from ₹637.33 to ₹635.50, reflecting updated assumptions around discount rate, profit margin and future P/E, while keeping revenue growth expectations broadly aligned with prior views. What's in the News Board meeting scheduled on Jan 17, 2026 at 12:30 IST to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider several corporate actions (company filing).ナラティブ更新 • Jan 22
ROSSARI: International Capacity Expansion Plans Will Drive Future Upside Potential
Analysts have revised their price target on Rossari Biotech lower from ₹795.75 to about ₹637.33, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. What's in the News A board meeting is scheduled on Jan 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).分析記事 • Jan 22
Analysts Have Lowered Expectations For Rossari Biotech Limited (NSE:ROSSARI) After Its Latest Results
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...ナラティブ更新 • Jan 08
ROSSARI: International Capacity Expansions Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹795.75, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E to better reflect current expectations. What's in the News A board meeting is scheduled on December 18, 2025 at 10:30 a.m. Indian Standard Time to consider and approve the incorporation of a wholly owned subsidiary in the Republic of Singapore (company filing).ナラティブ更新 • Dec 21
ROSSARI: Planned Singapore Subsidiary Will Drive Future International Expansion Upside
Analysts have reaffirmed their price target on Rossari Biotech at ₹795.75 per share, with only marginal tweaks to underlying assumptions such as discount rate, long term revenue growth, profit margin, and future P E multiple, reflecting a largely unchanged outlook on the company’s earnings trajectory and risk profile. What's in the News Board to meet on December 18, 2025, to consider incorporating a wholly owned subsidiary in the Republic of Singapore (Board Meeting) Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility, taking total installed capacity to 1,52,500 MTPA (Business Expansions) Commissioned 15,000 MTPA ethoxylation capacity at Unitop in Phase 1 of a 30,000 MTPA plan, with Phase 2 expected by the third quarter of fiscal 2026 (Business Expansions) Board approved an investment of up to USD 8 million in Rossari International Limited Company in Saudi Arabia to evaluate and assess expansion plans in international markets (Business Expansions) Board meeting scheduled on October 15, 2025, to approve unaudited financial results for the quarter and half year ended September 30, 2025 (Board Meeting) Valuation Changes The consensus analyst price target remains unchanged at ₹795.75 per share, indicating a stable fair value assessment.ナラティブ更新 • Dec 06
ROSSARI: Capacity Expansion And Saudi Subsidiary Investment Will Drive Future Upside
Narrative Update on Rossari Biotech Analysts have maintained their price target for Rossari Biotech at ₹795.75, citing largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. Taken together, these factors suggest limited change in the company’s fundamental outlook.ナラティブ更新 • Nov 22
ROSSARI: Additional Capacity Expansions Will Unlock Global Opportunities Ahead
Narrative Update on Rossari Biotech Analysts have maintained their fair value estimate for Rossari Biotech at ₹795.75, citing minimal changes in key financial assumptions and continued confidence in the company’s outlook. What's in the News Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility during the quarter, bringing total installed capacity to 1,52,500 MTPA.ナラティブ更新 • Nov 04
ROSSARI: New Expansion Projects Will Drive Global Market Penetration
Narrative Update on Rossari Biotech: Analyst Price Target Revision Analysts have revised Rossari Biotech’s fair value estimate downward from ₹826.67 to ₹795.75, citing slightly lower expectations for revenue growth and profit margins. What's in the News The company commissioned an additional 20,000 MTPA capacity at its Dahej facility, bringing total installed capacity to 1,52,500 MTPA (Key Developments).分析記事 • Oct 28
We Think That There Are More Issues For Rossari Biotech (NSE:ROSSARI) Than Just Sluggish Earnings
Rossari Biotech Limited's ( NSE:ROSSARI ) recent weak earnings report didn't cause a big stock movement. Our analysis...分析記事 • Jun 24
Here's Why Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights Rossari Biotech will host its Annual General Meeting on 30th of June Total pay for CEO Sunil Chari...
新しいナラティブ • Feb 10
Eco-friendly Solutions And New Capacities Will Strengthen Future Prospects
Strategic investments in capacity expansion and innovation in eco-friendly solutions are expected to drive revenue growth in domestic and international markets.分析記事 • Aug 17
Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All
Key Insights Rossari Biotech's Annual General Meeting to take place on 23rd of August Salary of ₹12.1m is part of CEO...分析記事 • Jun 14
Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • May 07
Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals
Investors were disappointed with Rossari Biotech Limited's ( NSE:ROSSARI ) earnings, despite the strong profit numbers...分析記事 • May 03
Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report
Last week, you might have seen that Rossari Biotech Limited ( NSE:ROSSARI ) released its full-year result to the...分析記事 • Feb 10
One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically
The analyst covering Rossari Biotech Limited ( NSE:ROSSARI ) delivered a dose of negativity to shareholders today, by...分析記事 • Sep 23
Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...分析記事 • Apr 06
Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Feb 19
Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues
Rossari Biotech Limited ( NSE:ROSSARI ) shareholders will have a reason to smile today, with the analysts making...分析記事 • Feb 17
Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...分析記事 • Feb 10
I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...分析記事 • Nov 24
Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • Oct 12
With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 3/31/2028 | 29,729 | 1,861 | 1,621 | N/A | 4 |
| 3/31/2027 | 26,522 | 1,499 | 1,123 | N/A | 2 |
| 6/30/2026 | 25,498 | 1,507 | N/A | N/A | N/A |
| 3/31/2026 | 23,964 | 1,492 | -1,996 | 651 | N/A |
| 12/31/2025 | 22,911 | 1,377 | N/A | N/A | N/A |
| 9/30/2025 | 22,221 | 1,366 | -1,690 | 731 | N/A |
| 6/30/2025 | 21,344 | 1,351 | N/A | N/A | N/A |
| 3/31/2025 | 20,803 | 1,364 | -211 | 1,374 | N/A |
| 12/31/2024 | 19,734 | 1,361 | N/A | N/A | N/A |
| 9/30/2024 | 19,245 | 1,388 | 17 | 1,162 | N/A |
| 6/30/2024 | 19,096 | 1,364 | N/A | N/A | N/A |
| 3/31/2024 | 18,306 | 1,307 | -880 | 433 | N/A |
| 12/31/2023 | 17,643 | 1,255 | N/A | N/A | N/A |
| 9/30/2023 | 16,898 | 1,168 | -341 | 631 | N/A |
| 6/30/2023 | 16,318 | 1,078 | N/A | N/A | N/A |
| 3/31/2023 | 16,559 | 1,073 | 1,187 | 1,516 | N/A |
| 12/31/2022 | 16,883 | 1,027 | N/A | N/A | N/A |
| 9/30/2022 | 17,275 | 995 | 729 | 990 | N/A |
| 6/30/2022 | 16,866 | 1,018 | N/A | N/A | N/A |
| 3/31/2022 | 14,830 | 977 | -89 | 294 | N/A |
| 12/31/2021 | 12,623 | 957 | N/A | N/A | N/A |
| 9/30/2021 | 10,438 | 948 | -342 | 129 | N/A |
| 6/30/2021 | 8,310 | 892 | N/A | N/A | N/A |
| 3/31/2021 | 7,093 | 802 | -103 | 478 | N/A |
| 12/31/2020 | 6,507 | 729 | N/A | N/A | N/A |
| 9/30/2020 | 6,031 | 695 | 198 | 1,045 | N/A |
| 6/30/2020 | 5,818 | 666 | N/A | N/A | N/A |
| 3/31/2020 | 6,001 | 653 | N/A | 568 | N/A |
| 3/31/2019 | 5,162 | 457 | N/A | 712 | N/A |
| 3/31/2018 | 2,922 | 254 | N/A | 254 | N/A |
| 3/31/2017 | 2,350 | 143 | N/A | 67 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ROSSARIの予測収益成長率 (年間12.9% ) は 貯蓄率 ( 6.9% ) を上回っています。
収益対市場: ROSSARIの収益 ( 12.9% ) Indian市場 ( 16.3% ) よりも低い成長が予測されています。
高成長収益: ROSSARIの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: ROSSARIの収益 ( 9% ) Indian市場 ( 11.1% ) よりも低い成長が予測されています。
高い収益成長: ROSSARIの収益 ( 9% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: ROSSARIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/23 11:37 |
| 終値 | 2026/07/23 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Rossari Biotech Limited 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Nitesh Dhoot | Anand Rathi Shares and Stock Brokers Limited |
| Abhishek Navalgund | Centrum Broking Limited |